Clinical trials: Injections
Adenocarcinoma of Gastric, Adenocarcinoma of Esophagogastric Junction
Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction
This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety and efficacy of IM96 CAR-T cells in treating patients with advanced adenocarcinoma of gastric/esophagogastric junction
- Trial name
- NCT07406984
- Testing
- IM96 CAR-T Cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Hepatocellular Carcinoma
AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma
A phase 1 study that aimed to assess the safety and anti-tumor activity of C-TCR055 injection in unresectable HCC patients.
- Trial name
- NCT03971747
- Testing
- AFP Specific T Cell Receptor T Cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai AbelZeta Ltd.
Coronary Artery Bypass Grafting (CABG), Chronic Heart Failure
A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure
B2278 is a human umbilical cord mesenchymal stem cell (HucMSCs) injection derived from the umbilical cord. It has the advantages of stronger immune regulation, stronger expansion capacity, lower immunogenicity, and greater…
- Conditions
- Coronary Artery Bypass Grafting (CABG), Chronic Heart Failure, Chronic Ischemic Cardiomyopathy
- Trial name
- NCT07265349
- Testing
- Mesenchymal stem cells(HucMSCs), CABG
- Where
- 4 sites in China
- Volunteers
- 51 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma
This is an open label clinical study: Phase Ia is a dose escalation phase, evaluating the safety, tolerability, RP2D, PK characteristics, and preliminary efficacy of IBR900 cell injection in the treatment of relapsed/refractory…
- Trial name
- NCT07073833
- Testing
- IBR900 cell injection, rituximab
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Imbioray (Hangzhou) Biomedicine Co., Ltd.
Age Related Macular Degeneration
Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMD
This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HLX04-O administered every 4 weeks in participants with wet age-related macular degeneration (wAMD)
- Trial name
- NCT04993352
- Testing
- recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Henlius Biotech
Cytomegalovirus Retinitis, HIV Infections
Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection
The purpose of this study is to make valganciclovir available, before it is approved for marketing, to HIV-infected patients who have cytomegalovirus (CMV) retinitis (eye infection) and cannot take drugs by injection.
- Trial name
- NCT00017784
- Testing
- Valganciclovir
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- Hoffmann-La Roche
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Study Assessing AR-13503 Implant in Subjects With nAMD or DME
First-in-Human Study of the Safety of AR-13503 Sustained Release Intravitreal Implant in Subjects with Neovascular Age-Related Macular Degeneration (nAMD) and Subjects with Diabetic Macular Edema (DME)
- Trial name
- NCT03835884
- Testing
- AR-13503 Implant 10.6 Dose, AR-13503 Implant 21.2 Dose, AR-13503 42.4 Dose
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Aerie Pharmaceuticals
Hepatitis B Virus (HBV)
Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) in Chronic Hepatitis B Patients
Hepatitis B virus (HBV) infection is a worldwide health problem. It has been proved that the persistence of HBV is associated with the failure to stimulate an efficient HBV-specific immune response.
- Trial name
- NCT04168333
- Testing
- T101 Group
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tasly Tianjin Biopharmaceutical Co., Ltd.
Tetanus
A Phase 4 Study to Evaluate the Effectiveness and Safety of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
Study sites were selected from hospitals across diverse regions of China. Approximately 6,000 participants who require passive immunization against tetanus due to various injuries (including those with severe wounds or heavily…
- Trial name
- NCT07347938
- Testing
- Siltartoxatug Injection, HTIG/TAT/F(ab')₂
- Where
- China
- Volunteers
- 6,000 people
- Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
Von Willebrand Disease
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B
To evaluate the effect of ARC1779, a therapeutic oligonucleotide ("aptamer") in patients with Type2B von Willebrand Disease.
- Trial name
- NCT00694785
- Testing
- ARC1779
- Volunteers
- 2 people
- Sponsor
- Archemix Corp.
Non-squamous Non-small-cell Lung Cancer
A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer
This trial is a randomized, double-blind, parallel-controlled, multicenter phase III clinical study. To evaluate the clinical efficacy of SIBP04 in patients with locally advanced, metastatic or recurrent non-squamous non-small…
- Trial name
- NCT05318443
- Testing
- SIBP04, Avastin, Paclitaxel
- Where
- China
- Volunteers
- 512 people
- Sponsor
- Shanghai Institute Of Biological Products
Peritoneal Dialysis Patients
Clinical Study of R744 to Peritoneal Dialysis Patients
This study will assess the efficacy and safety of subcutaneous or intravenous R744 in renal anemia patients on Peritoneal Dialysis.
- Trial name
- NCT00433849
- Testing
- R744
- Where
- 6 sites in Japan
- Volunteers
- 72 people
- Sponsor
- Chugai Pharmaceutical
Chronic Hepatitis B
A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)
This is a study of sequential therapy with AHB-137 injection followed by TVAX-008 injection in participants living with Chronic Hepatitis B (CHB).
- Trial name
- NCT07897448
- Testing
- AHB-137, TVAX-008
- Volunteers
- 105 people
- Sponsor
- Grand Theravac Life Sciences (Hangzhou) Co., Ltd.
NSCLC
Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer
The Phase 2 study described in this protocol will serve to evaluate the antitumor activity, safety and pharmacokinetic profile of Imprime PGG when combined with cetuximab and concomitant paclitaxel and carboplatin therapy in…
- Trial name
- NCT00874848
- Testing
- Imprime PGG Injection, Cetuximab, Paclitaxel
- Where
- 14 sites in United States, Germany
- Volunteers
- 90 people
- Sponsor
- HiberCell, Inc.
HER2-positive Recurrent or Metastatic Malignant Solid Tumor
Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor
This is a phase I study evaluating the safety and pharmacokinetics of MBS301 after intravenous administration in patients with HER-2 positive recurrent or metastatic malignant solid tumors
- Trial name
- NCT03842085
- Testing
- Recombinant Humanized Bispecific Monoclonal Antibody MBS301
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Cervical Dystonia
Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)
Phase 3, open-label, multi-center trial to evaluate the long-term safety, efficacy, and immunogenicity of up to four continuous treatment cycles of daxibotulinumtoxinA (DAXI) for injection.
- Trial name
- ASPEN-OLS (NCT03617367)
- Testing
- daxibotulinumtoxinA for injection
- Where
- 65 sites in United States, Austria and 7 more
- Volunteers
- 357 people
- Sponsor
- Revance Therapeutics, Inc.
Opioid-use Disorder
SUBLOCADE Rapid Initiation Study
This study is to evaluate the safety and tolerability of initiating SUBLOCADE™ treatment following a shorter period of transmucosal (TM) buprenorphine treatment.
- Trial name
- NCT03993392
- Testing
- TM buprenorphine, SUBLOCADE
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Indivior Inc.
Submental Fat
A Safety and Tolerability Study of 10XB-101 Injections in Adult Subjects With Extra Fat Under the Chin ("Double Chin")
The purpose of this research study is to find out more about an investigational drug, 10XB-101, for people with fat under their chin which they would like to remove.
- Trial name
- NCT04258761
- Testing
- 10XB-101 Solution for Injection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- 10xBio, LLC
Postoperative Cognitive Dysfunction in Patients With Aneurysmal Subarachnoid Hemorrhage
The Effect of Huperzine A Injection on Postoperative Cognitive Dysfunction in Patients With Aneurysmal Subarachnoid Hemorrhage: a Pilot Study
Under the premise of basic treatment, to explore the improvement effect of huperzine A injection on short-term and long-term neurocognitive dysfunction in patients with aneurysmal subarachnoid hemorrhage after…
- Trial name
- NCT05560373
- Testing
- Huperzine A injection, operational treatment, the best basic treatment, operational treatment, the best basic treatment, Huperzine A injection, interventional treatment, the best basic treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Wanbangde Pharmaceutical Group Co., LTD
Bone Cysts
Safety and Tolerability of I-040302 in Children and Young Adults With Solitary Bone Cysts
This is a randomised, controlled, open-label study of a single intralesional administration of I-040302 or a single bone marrow aspirate or a single steroid injection (methylprednisolone).
- Trial name
- NCT00459641
- Testing
- I-040302, Standard of Care
- Sponsor
- Kuros Biosurgery AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.